cyy-287, a novel pyrimidine-2,4-diamine derivative, inhibits tumor growth of EGFR-driven non-small cell lung cancer via the ERK pathway

In recent decades, EGFR-targeted tyrosine kinase inhibitors (TKIs) have been proven to be an effective therapy for EGFR-mutant non-small cell lung cancer (NSCLC). However, resistance to EGFR-TKIs limits their clinical application. In the present study, we investigate the antitumor effect and underly...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qianwen, Huang, Huijing, Zheng, Shuwen, Tang, Yelin, Zhang, Xiaodan, Zhu, Qianqian, Ni, Zefeng, Zheng, Xiaohui, Wang, Kun, Huang, Lehao, Zhao, Yunjie, Liu, Zhiguo, Qian, Jianchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828441/
https://www.ncbi.nlm.nih.gov/pubmed/36239356
http://dx.doi.org/10.3724/abbs.2022139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828441/
https://www.ncbi.nlm.nih.gov/pubmed/36239356
http://dx.doi.org/10.3724/abbs.2022139

Ejemplares similares